Organisers are glad to welcome Richard Marsden, Chief Executive Officer of Synairgen to the speaker line-up on the Day 1 of the event
Event in programme in brief:
April 11 (Day 1) will have presentations covering:
Novel approaches to management and prevention of COPD exacerbations (Wisla Wedzicha of Imperial College London);
Development of inhaled interferon beta for the treatment and/or prevention of virus-induced exacerbations of Asthma and COPD (Richard Marsden, Chief Executive Officer, Synairgen);
Adherence to inhaled therapy - the challenges and opportunities of digital technologies (Richard Costello, Professor, Royal College of Surgeons in Ireland);
Regulatory requirements, human factors and usability for inhaled drug- device combination products (Quan Yang, Pharmaceutical Assessor, MHRA).
In addition - a number of other exciting presentations covering Novel Therapeutic Approaches to COPD & Asthma and Advancements in Inhalation Device Development.
April 12 (Day 2) will cover topics of:
Genetic Driven Drug Discovery for Respiratory Disease (Jonathan Phillips, Principal Scientist, Inflammation, Amgen);
New Therapeutic Targets for COPD (Peter Barnes, Professor of Thoracic Medicine and Head of Respiratory Medicine, National Heart & Lung Institute);
From efficacy to effectiveness, the Salford lung study in COPD and now asthma (David Leather, Medical Vice President, Global Respiratory Franchise, GSK)
In addition - multiple presentations on the following areas: Early Detection - Molecular Phenotyping and Biomarker Development, Real World Studies and Disease Modifying Drugs and The Emerging Role of Smooth Muscle in Asthma.
To secure £500 Managers Special Discount* register your interest at http://www.asthma-copd.co.uk/prcom or contact Kieran Ronaldson on +44 (0)20 7827 6744 / [email protected]
Event is sponsored by: Vitalograph
+44 (0)20 7827 6000
LinkedIn – search "SMi Pharma"
Twitter – @SMIpharm and #AsthmaCOPDsmi
Asthma & COPD | 11 - 12 April 2018 | Copthorne Tara Hotel, London, UK